XORTX Therapeutics Inc.
XRTX
$2.28
-$0.03-1.30%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -45.36% | 27.23% | 17.71% | -28.10% | -42.97% |
| Depreciation & Amortization | -33.70% | -0.77% | 11.49% | 13.51% | -16.36% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -43.16% | -13.92% | 27.41% | -21.06% | -26.19% |
| Operating Income | 43.16% | 13.92% | -27.41% | 21.06% | 26.19% |
| Income Before Tax | -135.57% | -15.71% | -582.04% | -10.65% | -521.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -135.57% | -15.71% | -582.04% | -10.65% | -521.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -135.57% | -15.71% | -582.04% | -10.65% | -521.93% |
| EBIT | 43.16% | 13.92% | -27.41% | 21.06% | 26.19% |
| EBITDA | 41.35% | 11.51% | -28.25% | 18.82% | 26.55% |
| EPS Basic | -10.32% | 37.89% | -341.23% | 33.84% | -423.42% |
| Normalized Basic EPS | -10.34% | 37.88% | -340.46% | 33.86% | -423.50% |
| EPS Diluted | -10.53% | 37.89% | -341.75% | 33.84% | -424.34% |
| Normalized Diluted EPS | -10.34% | 37.88% | -340.46% | 33.86% | -423.50% |
| Average Basic Shares Outstanding | 113.53% | 86.30% | 99.77% | 67.26% | 30.46% |
| Average Diluted Shares Outstanding | 113.53% | 86.30% | 99.77% | 67.26% | 30.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |